Sven Berger

1.1k total citations
26 papers, 737 citations indexed

About

Sven Berger is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Sven Berger has authored 26 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Radiology, Nuclear Medicine and Imaging, 13 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Sven Berger's work include Monoclonal and Polyclonal Antibodies Research (19 papers), Chronic Lymphocytic Leukemia Research (6 papers) and CAR-T cell therapy research (6 papers). Sven Berger is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (19 papers), Chronic Lymphocytic Leukemia Research (6 papers) and CAR-T cell therapy research (6 papers). Sven Berger collaborates with scholars based in Germany, United States and France. Sven Berger's co-authors include Matthias Peipp, Thomas Valerius, Michael Dechant, Stefan Lohse, Thomas Beyer, Tanja Schneider‐Merck, Stefanie Derer, Jan G. J. van de Winkel, Paul W.H.I. Parren and Jeroen J. Lammerts van Bueren and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Sven Berger

25 papers receiving 717 citations

Peers

Countries citing papers authored by Sven Berger

Since Specialization

Citations

This map shows the geographic impact of Sven Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Berger more than expected).

Fields of papers citing papers by Sven Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Berger. The network helps show where Sven Berger may publish in the future.

Co-authorship network of co-authors of Sven Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Berger. A scholar is included among the top collaborators of Sven Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Berger. Sven Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 3673: Preclinical toxicology and pharmacology for the 4-1BB/HER2 bispecific PRS-343: A first-in-class costimulatory T cell engager 2017 ·Cancer Research ·Marlon J. Hinner, (unknown), Thomas J. Jaquin, Sven Berger, Manuela Dürr, Corinna Schlosser, (unknown), Christine Rothe, Louis A. Matis, Shane A. Olwill	2
2	NanoLuc Luciferase – A Multifunctional Tool for High Throughput Antibody Screening 2016 ·Frontiers in Pharmacology ·Nicolas Boute, Peter Lowe, Sven Berger, Martine Malissard, Alain Robert, Michael Tesar	54
3	Abstract B016: Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in humanized mouse model 2016 ·Cancer Immunology Research ·Marlon J. Hinner, (unknown), Corinna Schlosser, Thomas J. Jaquin, (unknown), Sven Berger, Alexander Wiedenmann, Gabriele Matschiner, Julia Schüler, Ulrich Moebius, Christine Rothe, Shane A. Olwill	1
4	A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells 2016 ·Molecular Cancer Therapeutics ·Matthieu Broussas, Nicolas Boute, (unknown), Sven Berger, (unknown), Thierry Champion, Alain Robert, Alain Beck, (unknown), Liliane Goetsch, Christian Bailly, Charles Dumontet, Thomas Matthes, Nathalie Corvaı̈a, Christine Klinguer‐Hamour	30
5	IBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society 2013 ·mAbs ·Peter‐Christian Klöhn, (unknown), Nora Zizlsperger, Yu Zhou, (unknown), Sven Berger, Kirstin A. Zettlitz, Gabriele Proetzel, (unknown), Richard H. J. Beǵent, Janice M. Reichert	11
6	Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies 2012 ·The Journal of Immunology ·Stefanie Derer, (unknown), Stefan Lohse, Andreas H. Scheel, Sven Berger, Christian Kellner, Matthias Peipp, Thomas Valerius	58
7	Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression 2012 ·Neoplasia ·Stefanie Derer, Sven Berger, (unknown), Tanja Schneider‐Merck, Katja Klausz, Stefan Lohse, Marije B. Overdijk, Michael Dechant, Christian Kellner, Iris Nagelmeier, Andreas H. Scheel, Jeroen J. Lammerts van Bueren, Jan G. J. van de Winkel, Paul W.H.I. Parren, Matthias Peipp, Thomas Valerius	18
8	IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA 2012 ·mAbs ·(unknown), (unknown), (unknown), (unknown), (unknown), Janice M. Reichert, (unknown), (unknown), (unknown), Sven Berger	18
9	Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function 2012 ·Methods in molecular biology ·Stefanie Derer, Christian Kellner, Sven Berger, Thomas Valerius, Matthias Peipp	13
10	Complement‐mediated tumor‐specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII) 2011 ·Cancer Science ·Katja Klausz, Sven Berger, Jeroen J. Lammerts van Bueren, Stefanie Derer, Stefan Lohse, Michael Dechant, Jan G. J. van de Winkel, Matthias Peipp, Paul W.H.I. Parren, Thomas Valerius	26
11	Fc‐engineered EGF‐R antibodies mediate improved antibody‐dependent cellular cytotoxicity (ADCC) against KRAS‐mutated tumor cells 2010 ·Cancer Science ·(unknown), Sven Berger, Stefanie Derer, Katja Klausz, Stefan Lohse, Michael Dechant, Greg A. Lazar, Tanja Schneider‐Merck, Matthias Peipp, Thomas Valerius	37
12	Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage 2009 ·The Journal of Immunology ·Tanja Schneider‐Merck, Jeroen J. Lammerts van Bueren, Sven Berger, (unknown), Patrick H.C. van Berkel, Stefanie Derer, Thomas Beyer, Stefan Lohse, Wim K. Bleeker, Matthias Peipp, Paul W.H.I. Parren, Jan G. J. van de Winkel, Thomas Valerius, Michael Dechant	167
13	Serum-free production and purification of chimeric IgA antibodies 2009 ·Journal of Immunological Methods ·Thomas Beyer, Stefan Lohse, Sven Berger, Matthias Peipp, Thomas Valerius, Michael Dechant	41
14	Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies 2008 ·Cancer Research ·Michael Dechant, (unknown), Sven Berger, Matthias Peipp, Thomas Beyer, Tanja Schneider‐Merck, Jeroen J. Lammerts van Bueren, Wim K. Bleeker, Paul W.H.I. Parren, Jan G. J. van de Winkel, Thomas Valerius	132
15	Autoreactive antibodies are present in sheep with Johne's disease and cross-react with Mycobacterium avium subsp. paratuberculosis antigens 2007 ·Microbes and Infection ·Sven Berger, John P. Bannantine, J.F.T. Griffin	8
16	Production and Characterization of Monoclonal Antibodies against a Major Membrane Protein ofMycobacterium aviumsubsp.paratuberculosis 2007 ·Clinical and Vaccine Immunology ·John P. Bannantine, (unknown), Judith R. Stabel, Sven Berger, J.F.T. Griffin, Michael L. Paustian	14
17	A comparison of ovine monocyte‐derived macrophage function following infection with Mycobacterium avium ssp. avium and Mycobacterium avium ssp. paratuberculosis 2006 ·Immunology and Cell Biology ·Sven Berger, Frank Griffin	20
18	Isolation of High-Affinity Single-Chain Antibodies against Mycobacterium avium subsp. paratuberculosis Surface Proteins from Sheep with Johne's Disease 2006 ·Clinical and Vaccine Immunology ·Sven Berger, (unknown), John P. Bannantine, J.F.T. Griffin	11
19	Woods, women and wine 1990 ·Sven Berger, (unknown), (unknown), (unknown), (unknown), Matthias Greiter, (unknown), (unknown), (unknown), (unknown), William Byrd, (unknown), (unknown), (unknown)	1
20	A MICRORADIOGRAPHIC AND X‐RAY CRYSTALLOGRAPHIC STUDY OF CALCIUM IN THE PINEAL BODY AND IN INTRACRANIAL TUMOURS 1958 ·Acta Pathologica Microbiologica Scandinavica ·Lennart Angervall, Sven Berger, H. Röckert	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact